| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
PLC 0.87 μM (IC50)
|
|---|---|
| ln Vitro |
ASM-IN-2 showed the highest activity in binding to ASM, with an IC50 value of 0.87 μM[1]. In the anti-proliferation experiment of human neuroblastoma SH-SY5Y cells detected by CCK8, ASM-IN-2 showed slight cytotoxicity at a higher concentration of 100 μM (cell survival rate was higher than 78%)[1].
|
| ln Vivo |
ASM-IN-2 (1 or 10 MG/KG, iv or ip) is rapidly absorbed (Tmax = 0.25 h) in male ICR mice, reaching higher maximum concentrations (Cmax = 4204.13 NG/ML) and moderate biotoxicity Utilization (F = 39.59%), suitable for research on antidepressants [1]. ASM-IN-2 (6, 12, 24 MG/KG, ip, 10 days) significantly reduced the immobility time of mice in the forced swimming test (FST) and tail suspension test (TST), and the effect was better than that of fluoxan Ting (12 MG/KG) (HY-W011235). ASM-IN-2 significantly increases BDNF expression and the level of sphingolipid ceramide in the cerebral cortex, and also improves oxidative stress levels by inhibiting AMS activity [1]. ASM-IN-2 (6, 12, 24 MG/KG, ip) reduces the levels of TNF-α, IL-1β and IL-6 in a dose-dependent manner in the CUMS mouse model, attenuating the inflammatory response[1]. ASM-IN-2 (6, 12, 24 MG/KG, ip) significantly increases the 5-HT content in mouse hippocampus tissue, thereby promoting more effective antidepressant activity by inhibiting ASM [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Corticosterone (CORT)-induced human neuroblastoma Tested Concentrations: 5, 10, 20 μM Incubation Duration: 24 h Experimental Results: Significantly attenuated corticosterone-induced damage in a dose-dependent manner and enhanced cell viability. Cell Cytotoxicity Assay[1] Cell Types: Human neuroblastoma cell line Concentration: 5, 10, 20, 50, 100 μM Incubation Duration: Experimental Results: Didn’t show any visible neurotoxicity at concentrations of 5, 10, and 20 μM, whereas exhibited weak cytotoxicity at a high concentration of 100 μM. |
| References |
| Molecular Formula |
C16H11BRCLN3O2
|
|---|---|
| Molecular Weight |
392.63
|
| CAS # |
2305789-66-4
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5469 mL | 12.7346 mL | 25.4693 mL | |
| 5 mM | 0.5094 mL | 2.5469 mL | 5.0939 mL | |
| 10 mM | 0.2547 mL | 1.2735 mL | 2.5469 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
